HRTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Heron Therapeutics Inc (HRTX) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The technical indicators, options data, and recent analyst downgrades suggest significant challenges for the company. The lack of positive catalysts, combined with legal setbacks and a bearish price trend, makes this stock unsuitable for the user's investment profile.
The MACD is below 0 and negatively contracting, indicating bearish momentum. The RSI is neutral at 35.748, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 0.386) but remains below the pivot point of 0.425. Overall, the technical indicators suggest a bearish trend.
NULL identified. No recent news or events suggest a positive catalyst for the stock.
The recent adverse legal decision invalidating Cinvanti patents significantly impacts Heron's revenue, as Cinvanti represents 60% of sales. Analysts have downgraded the stock, citing a lack of other product opportunities to offset the expected sales shortfall.
No financial data available for analysis. However, previous analyst commentary indicates a Q1 miss and concerns about revenue acceleration.
Analysts have downgraded the stock recently. H.C. Wainwright lowered the price target from $4 to $2 while maintaining a Buy rating, citing legal challenges. Needham downgraded the stock to Hold, citing the significant impact of the Cinvanti patent litigation and lack of alternative revenue streams.
